KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Convertible Debt (2017 - 2025)

Teladoc Health (TDOC) has disclosed Convertible Debt for 9 consecutive years, with $994.9 million as the latest value for Q4 2025.

  • Quarterly Convertible Debt fell 35.48% to $994.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $994.9 million through Dec 2025, down 35.48% year-over-year, with the annual reading at $994.9 million for FY2025, 35.48% down from the prior year.
  • Convertible Debt hit $994.9 million in Q4 2025 for Teladoc Health, roughly flat from $994.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $1.5 billion in Q4 2024 to a low of $306.3 million in Q4 2021.
  • Historically, Convertible Debt has averaged $1.3 billion across 5 years, with a median of $1.5 billion in 2022.
  • Biggest five-year swings in Convertible Debt: plummeted 77.8% in 2021 and later skyrocketed 401.24% in 2022.
  • Year by year, Convertible Debt stood at $306.3 million in 2021, then surged by 401.24% to $1.5 billion in 2022, then increased by 0.22% to $1.5 billion in 2023, then grew by 0.22% to $1.5 billion in 2024, then tumbled by 35.48% to $994.9 million in 2025.
  • Business Quant data shows Convertible Debt for TDOC at $994.9 million in Q4 2025, $994.0 million in Q3 2025, and $993.2 million in Q2 2025.